Arun Raghupathy, MD
Interventional Cardiology · Larkspur, CANPI 1245358324
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (49.0%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. 19 manufacturers reported payments, led by Boston Scientific at 32.5% of the total.
Across 305 payments — averaging $83.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$8K
- Abbott$8K
- Edwards Lifesciences$5K
- Medtronic$3K
- Abiomed$384
- Heartflow, Inc.$340
- plus $430 from 13 others
Across 34 payments — averaging $1281.02 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boston Scientific$44K
What the payments were for
- Consulting fees$4,32517%
- Travel & lodging$8,64434%
- Food & beverage$12,49349%
- Education$150%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 97 | $8,283 |
| Abbott | 69 | $7,786 |
| Edwards Lifesciences | 75 | $5,348 |
| Medtronic(2 entities) | 35 | $2,904 |
| Abiomed | 4 | $384 |
| Heartflow, Inc. | 4 | $340 |
| Philips North America LLC | 5 | $117 |
| Shockwave Medical, Inc | 3 | $46 |
| Johnson & Johnson | 3 | $43 |
| Reflow Medical Inc | 1 | $34 |
| Stryker | 1 | $32 |
| Teleflex LLC | 1 | $28 |
| Asahi Intecc USA, Inc. | 1 | $23 |
| E.r. Squibb & Sons, L.L.C. | 1 | $21 |
| Novartis | 1 | $20 |
| Portola Pharmaceuticals, LLC | 1 | $19 |
| B. Braun Interventional Systems Inc. | 1 | $17 |
| Amgen | 1 | $16 |
| AstraZeneca | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Watchman$5,038
- COREVALVE EVOLUT R$1,997
- MitraClip$1,859
- MitraClip System$1,125
- TRICLIP$981
- Mitra Clip system$979
- Edwards SAPIEN 3 Transcatheter Heart Valve$956
- GENERAL - THERAPIES$940
- PASCAL$604
- AMPLATZER Occluders$540
- CoreValve Evolut$262
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$238
- AMPLATZER$229
- ONYX FRONTIER$184
- AVEIR$126
- EVOQUE$110
How this compares
$25,476 in reported general payments places this provider in the 75th percentile of 585 interventional cardiology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 342 | $420,388 |
| XareltoRivaroxaban | 106 | $137,479 |
| Repatha SureclickEvolocumab | 62 | $63,409 |
| EntrestoSacubitril/Valsartan | 30 | $34,318 |
| JardianceEmpagliflozin | 32 | $27,747 |
| MultaqDronedarone Hcl | 12 | $24,526 |
| BrilintaTicagrelor | 28 | $17,928 |
| Repatha SyringeEvolocumab | 16 | $12,286 |
| Atorvastatin Calcium | 705 | $8,500 |
| Losartan Potassium | 464 | $6,476 |
| Metoprolol Succinate | 349 | $5,445 |
| Nebivolol Hcl | 41 | $4,838 |
| Ezetimibe | 153 | $4,457 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 12 | $4,138 |
| Rosuvastatin Calcium | 190 | $3,282 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $43 | $137,479106 claims |
| NovartisEntresto | $20 | $34,31830 claims |
| AstraZenecaBrilinta | $14 | $17,92828 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 585 interventional cardiology providers in California.
Other interventional cardiology in Larkspur
- Matthew Pricela Jolla$2.3M
- Frederick St GoarMountain View$2.2M
- Saibal KarThousand Oaks$1.1M
- Rahul SharmaStanford$1M
- Puneet KhannaRancho Mirage$1M
- Dennis SheehanRedwood City$900K
- Suhail DohadBeverly Hills$802K
- Curtiss Stinisla Jolla$759K
- Christian SpiesBurlingame$719K
- Evan ZahnLos Angeles$632K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.